NCT04718233View on ClinicalTrials.gov

Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

July 1, 2019

Conditions
Recurrent Pregnancy Loss
Interventions
DRUG

Sildenafil 25Mg Tablet

Sildenafil citrate at a dose of 25mg will be administered orally in patients with recurrent pregnancy loss

DRUG

Placebo Oral Tablet

placebo will be administered orally in patients with recurrent pregnancy loss

Trial Locations (1)

25187

Ain shams university maternity hospital, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT04718233 - Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss | Biotech Hunter | Biotech Hunter